African Trypanosomiasis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 60 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

African Trypanosomiasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'African Trypanosomiasis - Pipeline Review, H2 2014', provides an overview of the African Trypanosomiasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for African Trypanosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for African Trypanosomiasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for African Trypanosomiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the African Trypanosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the African Trypanosomiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
African Trypanosomiasis Overview 7
Therapeutics Development 8
Pipeline Products for African Trypanosomiasis - Overview 8
Pipeline Products for African Trypanosomiasis - Comparative Analysis 9
African Trypanosomiasis - Therapeutics under Development by Companies 10
African Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes 11
African Trypanosomiasis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
African Trypanosomiasis - Products under Development by Companies 14
African Trypanosomiasis - Products under Investigation by Universities/Institutes 15
African Trypanosomiasis - Companies Involved in Therapeutics Development 16
Sanofi 16
D-Pharm Ltd. 17
Scynexis, Inc. 18
Anacor Pharmaceuticals, Inc. 19
African Trypanosomiasis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
fexinidazole - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AN-5568 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DP-460 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DP-b99 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AN-3520 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SCYX-6759 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DDD-85646 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Oxabarole Backup Compound - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NVPBEZ-235 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
African Sleeping Sickness Program - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Inhibit Nitroreductase for Chagas Disease and African Trypanosomiasis - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit Bcl-2 for Infectious Disease and Oncology - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Peptides for African Sleeping Sickness - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules for Sleeping Sickness - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules for Malaria and African Trypanosomiasis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules for Leishmaniasis, Chagas disease and HAT - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules for Protozoal Infections - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
African Trypanosomiasis - Recent Pipeline Updates 51
African Trypanosomiasis - Dormant Projects 54
African Trypanosomiasis - Discontinued Products 55
African Trypanosomiasis - Product Development Milestones 56
Featured News & Press Releases 56
Aug 19, 2013: Positive Results for D-Pharm's Investigational Drugs in Models of Human African Trypanosomiasis and Malaria 56
Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness 56
Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables
Number of Products under Development for African Trypanosomiasis, H2 2014 8
Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
African Trypanosomiasis - Pipeline by Sanofi, H2 2014 16
African Trypanosomiasis - Pipeline by D-Pharm Ltd., H2 2014 17
African Trypanosomiasis - Pipeline by Scynexis, Inc., H2 2014 18
African Trypanosomiasis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
African Trypanosomiasis Therapeutics - Recent Pipeline Updates, H2 2014 51
African Trypanosomiasis - Dormant Projects, H2 2014 54
African Trypanosomiasis - Discontinued Products, H2 2014 55